Day: September 29, 2022

Aware®is a simple at-home device to increase sensitivity in breast self-exams. About 80% of breast cancer is detected by women themselves who notice changes in their breast. EZ Detect™ is a simple 2-minute, at-home test which detects an early warning sign of colorectal cancerIRVINE, Calif., Sept. 29, 2022 (GLOBE NEWSWIRE) — Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) today announced that the Company’s Aware® Breast Self Exam device and EZ Detect Colon Disease test are now being sold on Amazon and fulfilled by Amazon. Aware: https://www.amazon.com/gp/product/B010OVMR2S/ref=ewc_pr_img_1?smid=A12JU5SP5PIFD3&psc=1 EZ Detect: https://www.amazon.com/gp/product/B00EF2BPZ8/ref=ewc_pr_img_1?smid=A12JU5SP5PIFD3&psc=1 The Biomerica FDA-cleared Aware® Breast Self Exam device is a revolutionary way for women to enhance tactile...

Newtek is Positioning Itself to Become the Bank of the Future for Independently Owned Businesses BOCA RATON, Fla., Sept. 29, 2022 (GLOBE NEWSWIRE) — Newtek Business Services Corp., (NASDAQ: NEWT), an internally managed business development company (“BDC”), announced it has selected the Apiture Digital Banking Platform to support the digital capabilities of Newtek Bank, pending regulatory approvals and the close of the acquisition of the National Bank of New York City (“NBNYC”). Newtek plans to leverage Apiture’s Business Banking and Account Opening solutions in combination with Newtek’s existing suite of business and finance solutions and the Newtek Advantage™ to deliver a comprehensive suite of financial and business solutions and services to independent business owners. Newtek previously announced an agreement to acquire NBNYC,...

GFH009 Formulation is Near Physiological pH, While Still Achieving Desired Effect – GFH009 at pH 6.0 Decreased Potential for Infusion Reaction and Made Dosing Better Tolerated After Multiple Doses or Long-time Infusion –NEW YORK, Sept. 29, 2022 (GLOBE NEWSWIRE) — SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, announced today data from a bioequivalence study for GFH009, its potent, highly selective, clinical-stage small molecule that inhibits cyclin-dependent kinase 9 (CDK9). In the ongoing Phase 1 clinical trial of GFH009 monotherapy in patients with relapsed/refractory hematologic conditions, including acute myeloid leukemia and lymphoma, GFH009 is administered...

Graphene manufacturer will also be a featured keynote presenter TORONTO, Sept. 29, 2022 (GLOBE NEWSWIRE) — HydroGraph CleanPower Inc. (HG.CN) (the “Company” or “HydroGraph”), a commercial manufacturer of high-quality nanomaterials and alternative-energy fuels will exhibit at The Advanced Materials Show USA taking place on October 11 and 12 in Pittsburgh, PA. The Advanced Materials Show will be co-located with The Nanotechnology Show, as well as The Materials Science and Technology (MS&T) conference. The exhibition will provide a comprehensive showcase of the entire supply chain and the latest in high-performance materials technology for applications including aerospace, automotive, electronics, energy and medical technology. HydroGraph’s president, Kjirstin Breure, will be a keynote speaker on “Understanding the Macro Factors...

TORONTO, Sept. 29, 2022 (GLOBE NEWSWIRE) — iSIGN Media Solutions Inc. (“iSIGN” or “Company”) (TSX-V: ISD) (OTC: ISDSF), and its reseller, Smart City Services International (“SCSI”) are pleased to announce the launch of a fifty-vehicle pilot deployment of iSIGN’s HALO.fx technology, commencing on October 15, 2022 for twelve months. This paid pilot will equip fifty private transit buses operating in Mexico City with the HALO.fx node. Each node will capture occupancy levels, passenger ingress and egress data and gather information from nearby mobile devices. The information collected will address immediate concerns regarding fare-evasion detection, rider behaviour, route planning, and resource deployment. To a large degree, Mexico and most Latin American countries rely on currency payments by passengers. HALO.fx and PHACT technologies...

FARMINGTON HILLS, Mich., Sept. 29, 2022 (GLOBE NEWSWIRE) — Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced that it has appointed seven new Key Opinion Leaders (KOLs) across retina, cornea/refractive, and medical optometry to its Medical Advisory Board (MAB). In addition, Ronil Patel, M.S. has been promoted to Vice President, Business Development and Market Strategy. “The collective and extensive clinical experience on landmark ophthalmic trials over decades is central to this accomplished group of advisors being added to our MAB. Their guidance will be invaluable as we advance our late-stage candidates Nyxol and APX3330 through important clinical and regulatory...

Elanders will issue its Quarterly Report for the third quarter 2022 on Monday October 17 at 13:00 CET, followed by a conference call at 15:00 CET, hosted by President and CEO Magnus Nilsson and CFO Andréas Wikner. We invite fund managers, analysts and the media to participate in the conference call. The call-in details for the conference call have been updated. Please use one of the phone numbers below and dial in 5-10 minutes prior to the start time to join the conference call: Sweden: +46 (0) 8 5051 0086Germany: +49 (0) 211 8822 8324UK: +44 (0) 33 0551 0211USA: +1 646 843 4609 Participant code: 1948496# Agenda14:50 Conference number is opened 15:00 Presentation of quarterly results15:20 Q&A16:00 End of the conference During the conference call a presentation will be held. To access the presentation, please use this link: https://www.elanders.com/presentations For...

MELBOURNE, Australia, Sept. 29, 2022 (GLOBE NEWSWIRE) — Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease is delighted to announce the recent publication of a paper in the Journal of Precision Medicine authored by GTG science team members, Dr Erika Spaeth, Director of Clinical Affairs, Dr Richard Allman, Chief Scientific Officer, and Dr Gillian Dite, Senior Biostatistician. Publication highlights:Publication highlights the utility of GeneType Risk Prediction Tools in Precision Medicine Paper outlines the utility accepted for publication in Journal of Precision Medicine1 Publication highlights the importance of incorporating risk stratification in preventative care GeneType Risk Assessment Test outperforms traditional risk assessments...